Amylin deposition in the brain: A second amyloid in Alzheimer disease?

Annals of Neurology

Volumn 74, Issue 4, 2013, Pages 517-526

  Jackson, Kaleena ^a   Barisone, Gustavo A ^a   Diaz, Elva ^a   Jin, Lee Way ^a   DeCarli, Charles ^a   Despa, Florin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN; AMYLOID BETA PROTEIN; OLIGOMER;

AGING; ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; BIOACCUMULATION; BLOOD VESSEL; BRAIN BLOOD VESSEL; CAPILLARY; CELL VACUOLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; ENZYME LINKED IMMUNOSORBENT ASSAY; GRAY MATTER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; METABOLIC DISORDER; MICROVASCULATURE; MULTIINFARCT DEMENTIA; NON INSULIN DEPENDENT DIABETES MELLITUS; ONSET AGE; PANCREAS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TEMPORAL LOBE; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BRAIN; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; ISLET AMYLOID POLYPEPTIDE; MALE; RNA, MESSENGER;

EID: 84890121878     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.23956     Document Type: Article

References (45)

1. Hebert LE, Scherr PA, Bienias JL, et al. State-specific projections through 2025 of Alzheimer disease prevalence. Neurology 2004; 62: 1645.
2. Craft S,. The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. Arch Neurol 2009; 66: 300-305.
3. Sims-Robinson C, Kim B, Rosko A, Feldman EL,. How does diabetes accelerate Alzheimer disease pathology? Nat Rev Neurol 2010; 6: 551-559.
4. Debette S, Seshadri S, Beiser A, et al. Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline. Neurology 2011; 77: 461-468.
5. Nelson PT, Smith CD, Abner EA, et al. Human cerebral neuropathology of Type 2 diabetes mellitus. Biochem Biophys Acta 2009; 1792: 454-469.
6. Schneider JA, Arvanitakis Z, Bang W, Bennett DA,. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007; 69: 2197-2204.
7. Kivipelto M, Ngandu T, Laatikainen T, et al. Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. Lancet Neurol 2006; 5: 735-741.
8. Plassman BL, Williams JW Jr, Burke JR, et al. Systematic review: factors associated with risk for and possible prevention of cognitive decline in later life. Ann Intern Med 2010; 153: 182-193.
9. Whitmer RA, Sidney S, Selby J, et al. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 2005; 64: 277-281.
10. Naderali EK, Ratcliffe SH, Dale MC, et al. Obesity and Alzheimer's disease: a link between body weight and cognitive function in old age. Am J Alzheimers Dis Other Demen 2009; 24: 445-449.
11. Knight JA,. Diseases and disorders associated with excess body weight. Ann Clin Lab Sci 2011; 41: 107-121.
12. Tzourio C, Dufouil C, Ducimetiere P, Alperovitch A,. Cognitive decline in individuals with high blood pressure: a longitudinal study in the elderly: EVA Study Group: Epidemiology of Vascular Aging. Neurology 1999; 53: 1948-1952.
13. Carmelli D, Swan GE, Reed T, et al. Midlife cardiovascular risk factors, ApoE, and cognitive decline in elderly male twins. Neurology 1998; 50: 1580-1585.
14. Kuo HK, Jones RN, Milberg WP, et al. Effect of blood pressure and diabetes mellitus on cognitive and physical functions in older adults: a longitudinal analysis of the advanced cognitive training for independent and vital elderly cohort. J Am Geriatr Soc 2005; 53: 1154-1161.
15. Alonso A, Mosley TH Jr, Gottesman RF, et al. Risk of dementia hospitalization associated with cardiovascular risk factors in midlife and older age: the Atherosclerosis Risk in Communities (ARIC) study. J Neurol Neurosurg Psychiatry 2009; 80: 1194-1201.
16. Knopman DS, Mosley TH, Catellier DJ, Coker LH,. Fourteen-year longitudinal study of vascular risk factors, APOE genotype, and cognition: the ARIC MRI Study. Alzheimers Dement 2009; 5: 207-214.
17. Ohara T, Doi Y, Ninomiya T, et al. Glucose tolerance status and risk of dementia in the community: the Hisayama Study. Neurology 2011; 77: 1126-1134.
18. Craft S, Watson GS,. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 2004; 3: 169-178.
19. Zhao WQ, Townsend M,. Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease. Biochem Biophys Acta 2008; 1792: 482-496.
20. Qiu WQ, Folstein MF,. Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis. Neurobiol Aging 2006; 27: 190-198.
21. Westermark P, Andersson A, Westermark GT,. Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiol Rev 2011; 91: 795-826.
22. Despa S, Margulies KB, Chen L, et al. Hyperamylinemia contributes to heart dysfunction in obesity and diabetes, a study in humans and rats. Circ Res 2012; 110: 598-608.
23. Gong W, Liu ZH, Zeng CH, et al. Amylin deposition in the kidney of patients with diabetic nephropathy. Kidney Int 2007; 72: 213-218.
24. Prusiner SB, DeArmond SJ,. Prion diseases and neurodegeneration. Annu Rev Neurosci 1994; 17: 311-339.
25. Haass C, Selkoe DJ,. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 2007; 8: 101-112.
26. Guerreiro RJ, Gustafson DR, Hardy J,. The genetic architecture of Alzheimer's disease: beyond APP, PSENs and APOE. Neurobiol Aging 2012; 33: 437-456.
27. Querfurth HW, LaFerla FM,. Alzheimer's disease. N Engl J Med 2010; 362: 329.
28. Janson J, Ashley RH, Harrison D, et al. The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes 1999; 48: 491-498.
29. Anguiano M, Nowak RJ, Lansbury PT Jr,. Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that may be relevant to type II diabetes. Biochemistry 2002; 41: 11338-11343.
30. Casas S, Novials A, Reimann F, et al. Calcium elevation in mouse pancreatic beta cells evoked by extracellular human islet amyloid polypeptide involves activation of the mechanosensitive ion channel TRPV4. Diabetologia 2008; 51: 2252-2262.
31. Mattson MP, Goodman Y,. Different amyloidogenic peptides share a similar mechanism of neurotoxicity involving reactive oxygen species and calcium. Brain Res 1995; 676: 219-224.
32. Kawahara M, Kuroda Y, Arispe N, Rojas E,. Alzheimer's beta-amyloid, human islet amylin, and prion protein fragment evoke intracellular free calcium elevations by a common mechanism in a hypothalamic GnRH neuronal cell line. J Biol Chem 2000; 275: 14077-14083.
33. Despa S, Margulies KB, Bers DM, Despa F,. Patients with type-2 diabetes accumulate amylin amyloid oligomers in the heart-a source of Ca cycling mishandling. Circulation 2011; 124: A12006.
34. Janciauskiene S, Ahrén B,. Fibrillar islet amyloid polypeptide differentially affects oxidative mechanisms and lipoprotein uptake in correlation with cytotoxicity in two insulin-producing cell lines. Biochem Biophys Res Commun 2000; 267: 619-625.
35. Wendt T, Tanji N, Guo J, et al. Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetes nephropathy. J Am Soc Nephrol 2003; 14: 1383-1395.
36. Zraika S, Hull RL, Udayasankar J, et al. Oxidative stress is induced by islet amyloid formation and time-dependently mediates amyloid-induced beta cell apoptosis. Diabetologia 2009; 52: 626-635.
37. Barisone GA, Ngo T, Tran M, et al. Role of MXD3 in proliferation of DAOY human medulloblastoma cells. PLoS One 2012; 7: e38508.
38. Barzilai N, Huffman DM, Muzumdar RH, Bartke A,. The critical role of metabolic pathways in aging. Diabetes 2012; 61: 1315-1322.
39. Gurlo T, Ryazantsev S, Huang CJ, et al. Evidence for proteotoxicity in beta cells in type 2 diabetes: toxic islet amyloid polypeptide oligomers form intracellularly in the secretory pathway. Am J Pathol 2010; 176: 861-869.
40. Despa F,. Endoplasmic reticulum overcrowding as a mechanism of beta-cell dysfunction in diabetes. Biophys J 2010; 98: 1641-1648.
41. Alarcon C, Verchere CB, Rhodes CJ,. Translational control of glucose-induced islet amyloid polypeptide production in pancreatic islets. Endocrinology 2012; 153: 2082-2087.
42. O'Nuallain B, Williams AD, Westermark P, Wetzel R,. Seeding specificity in amyloid growth induced by heterologous fibrils. J Biol Chem 2004; 279: 17490-17499.
43. Laganowsky A, Liu C, Sawaya MR, et al. Atomic view of a toxic amyloid small oligomer. Science 2012; 335: 1228-1231.
44. Fu W, Ruangkittisakul A, MacTavish D, et al. Amyloid β (Aβ) peptide directly activates amylin-3 receptor subtype by triggering multiple intracellular signaling pathways. J Biol Chem 2012; 287: 18820-18830.
45. Bateman RJ, Munsell LY, Morris JC, et al. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med 2006; 12: 856-861.